Skip to content
Riskpilot
← Back to search
Sign in
Get full access
Blue Cell Therapeutics ApS
APS
Active
Advertising protection
CVR 39981610
Ole Maaløes Vej 3, 2200
København N
Research and experimental development on natural sciences and engineering
·
NACE 7210
Est. 2018 · 7 years old
11 employees
Monitor
Share
Denmark
/
Companies
/
Research and experimental development on natural sciences and engineering
/
Blue Cell Therapeutics ApS
Overview
Financials
People & ownership
Related companies
Loading company…
People & ownership
Management
Actively employed in the business
Name
Role
Member since
Current (1)
SP
Søren Paludan Sheikh
Chief Executive Officer
Chief Executive Officer
2019
Former (1)
TT
Thomas Tofte Hansen
Chief Executive Officer
Chief Executive Officer
2018 – 2019
Board of directors
Non-executive oversight
Name
Role
Member since
Current (4)
MU
Michael Ulveman
Board of Directors
Board of Directors
2023
AR
Anella Rogaczewski
Board of Directors
Board of Directors
2023
OH
Olav Hellebø
Chairman
Chairman
2025
OV
Ole Vahlgren
Board of Directors
Board of Directors
2025
Former (4)
SW
Sebastian Wehle
Board of Directors
Board of Directors
2024 – 2024
AR
André Rafal Rogaczewski
Board of Directors
Board of Directors
2020 – 2022
CT
Casper Tind Hansen
Board of Directors
Board of Directors
2021 – 2023
AV
Anders Vadsholt
Board of Directors
Board of Directors
2024 – 2025
Shareholders
As of last annual report
Shareholder
Type
Ownership
Votes
Since
SPSheikh Holding ApS
Company
33.33–49.99%
33.33–49.99%
2024
ANDRÉ ROGACZEWSKI HOLDING II ApS
Company
33.33–49.99%
33.33–49.99%
2024
SEIER CAPITAL A/S
Company
5–9.99%
5–9.99%
2024
Leif Helth Jensen
Individual
5–9.99%
5–9.99%
2019
TTH HOLDING ApS
Company
5–9.99%
5–9.99%
2020
SPLUSH GROUP ApS
Company
5–9.99%
5–9.99%
2019
SHEIKH HOLDING ApS
Company
50–66.65%
50%
2019
REGTISS ApS
Company
5–9.99%
5–9.99%
2019
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
More on Blue Cell Therapeutics ApS
Overview →
Headline figures, risk assessment and company summary
Financials & key figures →
Revenue, EBITDA, balance sheet and 5-year trend
Related companies →
Corporate hierarchy, parent and subsidiary network